Cargando…

Ultrasound‐controlled drug release and drug activation for cancer therapy

Traditional chemotherapy suffers from severe toxicity and side effects that limit its maximum application in cancer therapy. To overcome this challenge, an ideal treatment strategy would be to selectively control the release or regulate the activity of drugs to minimize the undesirable toxicity. Rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Li, Liao, Zhihuan, Luo, Zheng, Wu, Yun‐Long, Herrmann, Andreas, Huo, Shuaidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190934/
https://www.ncbi.nlm.nih.gov/pubmed/37323693
http://dx.doi.org/10.1002/EXP.20210023
_version_ 1785043375771090944
author Tu, Li
Liao, Zhihuan
Luo, Zheng
Wu, Yun‐Long
Herrmann, Andreas
Huo, Shuaidong
author_facet Tu, Li
Liao, Zhihuan
Luo, Zheng
Wu, Yun‐Long
Herrmann, Andreas
Huo, Shuaidong
author_sort Tu, Li
collection PubMed
description Traditional chemotherapy suffers from severe toxicity and side effects that limit its maximum application in cancer therapy. To overcome this challenge, an ideal treatment strategy would be to selectively control the release or regulate the activity of drugs to minimize the undesirable toxicity. Recently, ultrasound (US)‐responsive drug delivery systems (DDSs) have attracted significant attention due to the non‐invasiveness, high tissue penetration depth, and spatiotemporal controllability of US. Moreover, the US‐induced mechanical force has been proven to be a robust method to site‐selectively rearrange or cleave bonds in mechanochemistry. This review describes the US‐activated DDSs from the fundamental basics and aims to present a comprehensive summary of the current understanding of US‐responsive DDSs for controlled drug release and drug activation. First, we summarize the typical mechanisms for US‐responsive drug release and drug activation. Second, the main factors affecting the ultrasonic responsiveness of drug carriers are outlined. Furthermore, representative examples of US‐controlled drug release and drug activation are discussed, emphasizing their novelty and design principles. Finally, the challenges and an outlook on this promising therapeutic strategy are discussed.
format Online
Article
Text
id pubmed-10190934
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101909342023-06-14 Ultrasound‐controlled drug release and drug activation for cancer therapy Tu, Li Liao, Zhihuan Luo, Zheng Wu, Yun‐Long Herrmann, Andreas Huo, Shuaidong Exploration (Beijing) Review Articles Traditional chemotherapy suffers from severe toxicity and side effects that limit its maximum application in cancer therapy. To overcome this challenge, an ideal treatment strategy would be to selectively control the release or regulate the activity of drugs to minimize the undesirable toxicity. Recently, ultrasound (US)‐responsive drug delivery systems (DDSs) have attracted significant attention due to the non‐invasiveness, high tissue penetration depth, and spatiotemporal controllability of US. Moreover, the US‐induced mechanical force has been proven to be a robust method to site‐selectively rearrange or cleave bonds in mechanochemistry. This review describes the US‐activated DDSs from the fundamental basics and aims to present a comprehensive summary of the current understanding of US‐responsive DDSs for controlled drug release and drug activation. First, we summarize the typical mechanisms for US‐responsive drug release and drug activation. Second, the main factors affecting the ultrasonic responsiveness of drug carriers are outlined. Furthermore, representative examples of US‐controlled drug release and drug activation are discussed, emphasizing their novelty and design principles. Finally, the challenges and an outlook on this promising therapeutic strategy are discussed. John Wiley and Sons Inc. 2021-12-28 /pmc/articles/PMC10190934/ /pubmed/37323693 http://dx.doi.org/10.1002/EXP.20210023 Text en © 2021 The Authors. Exploration published by Henan University and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Articles
Tu, Li
Liao, Zhihuan
Luo, Zheng
Wu, Yun‐Long
Herrmann, Andreas
Huo, Shuaidong
Ultrasound‐controlled drug release and drug activation for cancer therapy
title Ultrasound‐controlled drug release and drug activation for cancer therapy
title_full Ultrasound‐controlled drug release and drug activation for cancer therapy
title_fullStr Ultrasound‐controlled drug release and drug activation for cancer therapy
title_full_unstemmed Ultrasound‐controlled drug release and drug activation for cancer therapy
title_short Ultrasound‐controlled drug release and drug activation for cancer therapy
title_sort ultrasound‐controlled drug release and drug activation for cancer therapy
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190934/
https://www.ncbi.nlm.nih.gov/pubmed/37323693
http://dx.doi.org/10.1002/EXP.20210023
work_keys_str_mv AT tuli ultrasoundcontrolleddrugreleaseanddrugactivationforcancertherapy
AT liaozhihuan ultrasoundcontrolleddrugreleaseanddrugactivationforcancertherapy
AT luozheng ultrasoundcontrolleddrugreleaseanddrugactivationforcancertherapy
AT wuyunlong ultrasoundcontrolleddrugreleaseanddrugactivationforcancertherapy
AT herrmannandreas ultrasoundcontrolleddrugreleaseanddrugactivationforcancertherapy
AT huoshuaidong ultrasoundcontrolleddrugreleaseanddrugactivationforcancertherapy